COVID-19 and Diabetes
(Information and Ressources)
AHNIClasses
(Oral and Non Insulin Agents)
Classes (top of the list) Cost price per molecule 2 Biguanides 1 Alpha-Glucosidase Inhibitor 9 DPP-4 Inhibitors 8 SGLT2 Inhibitors 5 Insulin Secretagogue 4 Thiazolidinediones (TZD) 6 GLP-1R Agonists
InsulinesInsulin
Mode de vieLifestyle

Nutrition


BMI Calculator


Classification

  • Healthy Weight (BMI > 18.5)
  • Overweight (BMI > 25)
  • Obesity class 1 (BMI > 30)
  • Obesity class 2 (BMI > 35)
  • Obesity class 3 (BMI > 40)
Just the Basics A Glance at Meal Planning DQ Meal and Physical Activity Log Glycemic Index Tool Canada's Food Guide

Physical Activity

Physical Activity and Diabetes Physical Activity Interactive Decision Tool Introductory Resistance Program Resistance Exercises Aerobic Exercises Benefits of Physical Activity Planning for Regular Physical Activity Participaction
GlucometerBlood Glucose Monitoring

Glucose Logbook

Printable

Choosing the Appropriate Device

Interactive Guide

Dexcom G6®

Order Form Videos (see video tab)

Freestyle LibreTM

Autorisation of payment formulary RAMQ Eligibilty criteria et renewal Videos (see video tab) FAQ

Blood Glucose Meters

Product Guide DQ (FR)

Comparison Charts

System Flash/CGM Meter Characteristics

Blood Glucose Monitoring

Recommendation Tool / Frequency Interactive Guide SMBG

Strips

Reimbursement and Coding (FR) Clinical Situations Update 2017 (FR) (2017-11-15)
CoverageCoverage
(Government)

Codes / Indications RAMQ

EN23

When a sulfonylurea is not tolerated or ineffective.

  • Amaryl®

EN167

For the treatment of people with type 2 diabetes:
- As monotherapy when metformin and a sulfonylurea are contraindicated or not tolerated.

  • Invokana®
  • Januvia®
  • Jardiance®
  • Nesina®
  • Trajenta®

EN148

For the treatment of people with type 2 diabetes:
- In combination with metformin, when a sulfonylurea is contraindicated, not tolerated or ineffective.

  • Invokana®
  • Onglyza®
  • Januvia®
  • Jardiance®
  • Nesina®
  • Forxiga®

EN149

For the treatment of people with type 2 diabetes:
- In combination with a sulfonylurea, when metformin is contraindicated, not tolerated or ineffective.

  • Invokana®
  • Onglyza®
  • Nesina®
  • Forxiga®

EN150

For the treatment of people with type 2 diabetes:
When a sulfonylurea is contraindicated, not tolerated or ineffective; AND
- When the daily doses of metformin have been stable for at least a month.

  • Janumet®
  • Janumet®XR
  • Komboglyze®
  • JentaduetoTM
  • KazanoTM
  • Xigduo®

EN179

For the treatment of type 2 diabetes, in combination with one or more antidiabetic agents, in persons with a history of atherosclerotic heart disease (ASIC) or atherosclerotic vascular disease (ASK) and whose glycated hemoglobin (HbA1c) is ≥ 7%.

The nature of atherosclerotic heart disease (MCAS) or atherosclerotic vascular disease (MVAS) should be provided upon request by the Régie.

  • Jardiance®

EN219

For the treatment of people with type 2 diabetes whose optimal maximum dose of metformin has been stable for at least one month.
Individuals must also meet the requirements of the recognized indication for the payment of empagliflozin.

  • SynjardyTM
Endocrinology (2020-04-29) (FR) Complete List (2020-04-29) (FR)

Cost

Cost price per molecule

NIHB Canada (Non-Insured Health Benefits)

Drug Benefit List

Patient Exception

Form

Form

Reimbursement
(exception drugs)

Ozempic®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes.
  • When a sulfonylurea is contraindicated, not tolerated or ineffective.
  • Authorization is given for a maximum weekly dose of 1mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

To note:

  • Unlike other GLP-1RA (Victoza and Trulicity), your patients do not need to have tried an iDPP4 or have a BMI > 30 to start treatment.
  • Both doses (0.5mg and 1mg) are reimbursed.

Victoza®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.8 mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

Trulicity®

For the treatment of people with type 2 diabetes:

  • In combination with metformin, for the treatment of people with type 2 diabetes with inadequate glycemic control and with a body mass index (BMI) above 30 kg/m2.
  • When a DPP-4 inhibitor is contraindicated, not tolerated or ineffective.
  • The maximum duration of each authorization is 12 months.
  • At the time of the first request to extend treatment, the physician is required to provide proof of benefit through a glycosylated hemoglobin (HbA1c) reduction of at least 0.5% or through the achievement of a target value of 7% or less.
  • Authorization is given for a maximum daily dose of 1.5 mg.
  • Inefficacy means non-achievement of an HbA1c value tailored to the patient.

BasaglarMC / Levemir® / Toujeo® / Tresiba®

For the treatment of diabetes when a prior trial with intermediate-acting insulin did not adequately control the glycemic profile without causing an episode of serious hypoglycemia or frequent episodes of hypoglycemia.

Degludec U100 et U200
Tresiba® Detemir
Levemir® Dulaglutide
Trulicity® Glargine
BasaglarTM Glargine U300
Toujeo® Liraglutide
Victoza® Semaglutide
Ozempic®

Strips

Reimbursement and Coding (FR) Update 2017 (2017-11-15) (FR)

Freestyle LibreTM

Autorisation of payment formulary RAMQ Eligibilty criteria et renewal
Fonction RénaleRenal Function
(Medication and Adjustment Chart)
Chart Cockcroft-Gault Equation Therapeutic Considerations
Educational Videos
Digital Applications
RessourcesResources

Diabetes Screening

CANRISK

Education

The Basics Type 2 The Basics Type 1 Hyperglycemia (DQ) Hypoglycemia / Glucagon

Injection Technique FIT Plus

Insulin Pen Needle Length Site Selection and Rotation Lipohypertrophy (1) Lipohypertrophy (2) Pregnant Women (1) Pregnant Women (2) Elderly (1) Elderly (2) Kids Teens (1) Teens (2)

Sick-Day Management

Jessie Haggai Tool SADMANS (Appendix 8 DC) Keeping People Safe During Sickdays Tool (DC)

Cannabis

Diabetes Canada Position Statement

Travel

See DQ Tab

Driving

Drive Safe with Diabetes Licence (SAAQ) Recommendations (DC) Assessment Form See DQ Tab

The Diabetes Distress Scale (DDS)

Questionnaire How to use it in practice

Eye Care

Diabetes Canada Retinopathy

Foot Care

AIISPQ (FR) Diabetes and Foot Care: A Checklist Rapid Screening for Neuropathy - Monofilament Testing Rapid Screening for Neuropathy - Vibration Tuning Fork

Pregnancy

Diabetes Canada Screening for Gestational Diabetes Mellitus (GDM)

Smoking and Diabetes

Management Recommendations

Ramadan

Diabetes Canada Position Statement Calendar Dates Diabetes Québec

Vaccination

Diabetes Canada Protocole d'immunisation du Québec (PIQ)
Diabetes CanadaDiabetes Canada
(DC)

Web Site

Link to Diabetes Canada

Canadian Diabetes Association Guidelines 2018

Complete Summary (to follow) Printable Pocket Guide

Update

To Follow

Diagnosis Guide

Quick Reference Guide

Individualization Guides

A1C Target Metformin and then what? SMBG Frequency and Pattern Antidiabetics Therapies Algorithm

Vascular Protection Guides

Quick Reference Guide Reducing Vascular Risk Quick Reference - ABCDEs
Diabetes QuebecDiabetes Québec
(DQ)

Web site

Link to Diabetes Québec Product Guide (FR)

Travel

Plan Your Trip Travel Guide Letter of Authorization

Driving

Law and Regulations

Ramadan

Ramadan
Mise à jourUpdate 2020-05-24
(Recent Additions)

2020-05-24

Resources

  • Injection Technique FIT Plus - Updating information

2020-04-29

Coverage

2020-04-26

Blood Glucose Monitoring - FreeStyle LibreTM

2020-04-21

Diabetes Québec

Ressources

2020-04-18

Educational Videos

2020-04-10

CLASSES - SGLT2 Inhibitors

  • Forxiga® is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and CV risk factors or established CV disease (see CLINICAL TRIALS).

2020-04-07

Renal Function

2020-04-04

CLASSES - GLP-1R

2020-03-09

Digital Applications

2020-03-04

Classes + Insulin

  • New indications for Fiasp® and Victoza® see product monograph Fiasp® / Victoza®

2020-03-01

Classes

2020-02-09

Classes + Insulin

  • Adding of clinical trials

2020-01-15

Videos / Visual Tools / Applications

2019-12-26

Consultant

  • Jessie Haggai
    Proprietary Pharmacist - Diabetes Educator
    (see Contact us tab)
    Ms. Haggai joins the team as a consultant.

2019-12-25

Classes + Insulin

2019-11-30

Coverage

  • RAMQ Codes update (PDF)

2019-11-26

Classes + Insulin

  • The product monograph is now available

2019-11-16

Video

2019-11-14

GLP-1RA / Coverage

2019-11-10

Ressources

2019-11-03

Blood Glucose Monitoring

2019-10-27

Drug and Renal Function

Blood Glucose Monitoring

  • Freestyle LibreTM now working on Android

2019-10-10

Resources

Education

  • Nasal Glucagon BaqsimiTM - Health Canada Approval September 25 th
  • Nasal Glucagon BaqsimiTM - Information
  • Nasal Glucagon BaqsimiTM - Monograph

2019-10-03

Resources

2019-09-15

Blood Glucose Monitoring

2019-09-02

Education / Hypoglycemia / Glucagon

2019-08-15

Coverage

  • Glargine U300 Toujeo® now covered by the Quebec Health Insurance Board (RAMQ) according to certain criteria

2019-08-04

Blood Glucose Monitoring

  • Update of the Intercative Guide
  • Update of the Comparison Charts (PDF)

2019-07-19

Coverage

  • The FreeStyle LibreTM glucose monitoring flash system is now covered by the Quebec Health Insurance Board (RAMQ) according to certain criteria (see Coverage or Blood Glucose Monitoring tab)
  • RAMQ Codes update (PDF)

2019-06-20

GLP-1RA

  • Semaglutide Ozempic®
    New 4 mg flextouch maintenance pen. The 2 mg pen for the maintenance dose is no longer available

2019-05-31

Coverage

  • RAMQ Codes update (PDF)

2019-04-30

Drug and Renal Function

  • Update of the Renal Function Adjustment Chart

2019-04-11

Coverage

  • RAMQ Codes update (PDF)

2019-03-20

Blood Glucose Monitoring

  • New - Tab now completed

2019-03-07

Coverage

  • RAMQ Codes update (PDF)

2019-02-01

Coverage

  • RAMQ Codes update (PDF)

2018-12-19

Coverage

  • RAMQ Codes update (PDF)
  • SynjardyTM now code EN219

2018-11-23

Coverage

  • RAMQ Codes update (PDF)
  • Xigduo® and SynjardyTM now code EN150

2018-10-20

SGLT2

  • Adding - Ertugliflozin SteglatroTM
  • Adding - Ertugliflozin and Metformin SeglurometTM
  • Adding - Ertugliflozin and Sitagliptin SteglujanTM

Drug and Renal Function

  • New Chart Adjustment of the Medication with Renal Insufficiency

2018-10-01

Full update of the application

New

  • Addition of a search function
  • Overall improvement of performance and stability
  • Available soon for all Canadian provinces (in English only)

2018-09-27

Coverage

  • RAMQ Codes update (PDF) - Jardiance® now three codes EN148 - EN167 and EN179
  • Xigduo® and SynjardyTM now code EN199
  • Trajenta® now code EN148 and EN167
  • Degludec U100 and U200 now exception drugs (form)

2018-06-23

GLP-1RA

  • New document - Titration Protocol (Victoza® - Ozempic®- Trulicity® - AdlyxineTM)

2018-06-14

Drug and Renal Function

  • Update of the Renal Function Adjustment Chart

2018-05-26

Coverage

  • RAMQ Codes update (PDF) - Invokana® now three codes EN148, EN149 and EN167

2018-04-25

Lifestyle

  • New document - Meal and Physical Activity Log (PDF)

Insulin

  • New document - Basal Insulin Adjustments (PDF)

2018-04-15

Diabetes Canada

  • New Diabetes Canadian Guidelines as April 9, 2018

Drug and Renal function

  • New Chart Adjustment of the Medication with Renal Insufficiency

Classes

  • New Vascular Protection Data for SGLT2 and GLP-1RA classes